News

Friday July 9, 2021

XF-73 Phase 2b data to be presented at ECCMID

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Successful XF-73 nasal gel Phase 2b study data to be presented at 2021 ECCMID Congress Infection prevention expert, Professor Julie Mangino MD […]

Tuesday July 6, 2021

NTCD-M3 RD Agreement with US Dept Veterans Affairs

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma and US Department of Veterans Affairs enter into Cooperative Research and Development Agreement to further research NTCD-M3 for prevention of […]

Friday July 2, 2021

Scientific Advisor, Professor Dale Gerding, to chair C. diff. Foundation Symposium

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Scientific Advisor Prof Dale Gerding to chair C. diff. Foundation Symposium Brighton, United Kingdom – 02 July 2021 – Destiny Pharma plc (AIM: DEST), […]